Psoriasis (Auckland, N.Z.)最新文献

{"title":"Sugary Drinks and High-Fat Foods are Associated with Poor Treatment Response in Psoriasis: A Prospective Study in Shanghai.","authors":"Jiankun Song, Yue Luo, Rui Zhang, Xiangjin Gao, Fanlingzi Shen, Ruiqi Cai, Jinrong Lu, Haotian Xu, Xin Ma, Bin Li, Wencheng Jiang, Ruiping Wang","doi":"10.2147/PTT.S617180","DOIUrl":"10.2147/PTT.S617180","url":null,"abstract":"<p><strong>Purpose: </strong>While dietary factors are known to be associated with the development and progression of psoriasis, their effect on treatment efficacy remains unclear. Therefore, this study aimed to elucidate the influence of tea consumption, sugar drinks, and high-fat foods on the treatment response in psoriasis.</p><p><strong>Patients and methods: </strong>We undertook a prospective cohort study comprising 559 patients with psoriasis from Shanghai Skin Disease Hospital between 2022 and 2024. Data on demographics, lifestyle (including tea, sugary drinks, and high-fat food consumption), and disease severity (PASI, BSA, PGA) were collected via structured questionnaires at baseline, week 4, and week 8. The primary endpoints were the proportions of patients achieving PASI 50 responses at week 8. Multivariable logistic regression was used to estimate odds ratios with 95% confidence intervals, adjusting for age, sex, BMI, smoking, alcohol, and treatment regimen. Data were analyzed using SAS 9.4 software.</p><p><strong>Results: </strong>In the psoriasis cohort (mean age 48.5 years; 73.2% male), 37.1% and 68.7% of patients consumed sugar drinks and high-fat foods ≥2 times/week, respectively. Frequent sugar drinks consumption (≥4 times/week) was independently associated with significantly reduced odds of achieving PASI 50 (adjusted OR=0.24, 95% CI: 0.08-0.75) and PASI 75 (adjusted OR=0.27, 95% CI: 0.07-1.00) at week 8. Moderate intake of high-fat foods (2-3 times/week) showed an inverse, borderline significant association with PASI 50 at week 4 (adjusted OR=0.68, 95% CI: 0.45-1.00). Tea consumption showed a non-significant association with treatment response (e.g, week 8 PASI 50 adjusted OR=1.44, 95% CI: 0.88-2.35), warranting further investigation in larger cohorts.</p><p><strong>Conclusion: </strong>This study demonstrates that high consumption of sugar drinks and high-fat foods is associated with suboptimal treatment response in psoriasis. Tea consumption was not significantly associated with treatment outcomes, although further investigation with larger cohorts may be warranted. These findings highlight the importance of integrating dietary assessment and counseling into comprehensive psoriasis management.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"617180"},"PeriodicalIF":5.2,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13380286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148498514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotype-Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study.","authors":"Xuan Deng, Yusha Chen, Xinli Liu, Jianxia Xiong, Runlu Hu, Sijian Liao, Wei Li, Kun Huang","doi":"10.2147/PTT.S613304","DOIUrl":"10.2147/PTT.S613304","url":null,"abstract":"<p><strong>Purpose: </strong>To explore genotype-phenotype associations of <i>IL36RN</i> variants and clinical outcomes of spesolimab treatment in acrodermatitis continua of Hallopeau (ACH).</p><p><strong>Patients and methods: </strong>This multicenter retrospective study included 14 ACH patients with <i>IL36RN</i> genotyping from 2019 to 2025. Clinical features were compared across all genotypes. Medical records of individuals who received spesolimab were reviewed to describe treatment responses, with a follow-up observation period up to 56 weeks.</p><p><strong>Results: </strong>Compared with monoallelic or wild-type genotypes, biallelic <i>IL36RN</i> variants were associated with earlier disease onset age (23 vs 48 and 47 years, <i>P</i> <0.05) and higher baseline disease severity (median GPPGA score, 4 vs 3 and 2, <i>P</i> <0.001). Among 6 patients with biallelic, refractory ACH who received spesolimab, including 3 isolated cases that were administered at a 450-mg dose, overall percentage improvement across disease activity and patient-reported measures occurred rapidly, reaching 54% at week 1 and 74% at week 4. Relapse occurred in 4 patients between weeks 31 and 44, with disease activity remaining lower than baseline and improvement observed after re-treatment.</p><p><strong>Conclusion: </strong>Spesolimab was associated with clinical improvement in refractory ACH with biallelic <i>IL36RN</i> mutations, including isolated ACH treated with a 450-mg dose, supporting further evaluation of dose individualization below the approved 900-mg regimen for GPP flares.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"613304"},"PeriodicalIF":5.2,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13378514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148581519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Medicine in Psoriasis - A Long Road Ahead?","authors":"Tom M Hillary","doi":"10.2147/PTT.S595079","DOIUrl":"10.2147/PTT.S595079","url":null,"abstract":"<p><strong>Background: </strong>Biologic therapies targeting IL‑17 and IL‑23 have revolutionized psoriasis management, enabling rapid and durable disease control. Yet treatment selection still follows a trial‑and‑error approach, and clinically validated biomarkers for personalization remain absent.</p><p><strong>Objective: </strong>To outline current challenges in biomarker development for psoriasis and describe the design and aims of the PICASSO prospective cohort as a platform for future personalized medicine.</p><p><strong>Current challenges: </strong>Despite evidence that IL‑17/IL‑23 inhibitors may induce disease modification through effects on effector, memory, and regulatory immune cells, reliable predictive or prognostic biomarkers have not emerged. Barriers include complex pathogenesis, universally high biologic efficacy reducing need for stratification, inconsistent findings from genetic or transcriptomic studies, and the multifactorial nature of comorbidities.</p><p><strong>Methods picasso prospective cohort psoriasis follow-up: </strong>PICASSO is a 10‑year prospective biobank/registry enrolling patients within three years of disease onset. Biological samples are longitudinally linked to clinical and epidemiological data, with follow‑ups every 2.5 years. The ultimate aim is to identify biomarkers predicting disease trajectory.</p><p><strong>Conclusion: </strong>Personalized psoriasis care requires biomarkers predicting progression and comorbidity risk. PICASSO represents a step toward disease‑modifying, preventive precision medicine.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"595079"},"PeriodicalIF":5.2,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics, Healthcare Resource Utilization, and Costs of Patients with Generalized Pustular Psoriasis in Taiwan: A National Claims Database Study.","authors":"Hsiu-Ting Chien, Chien-Yu Tseng, Chun-Wei Lu, Wen-Hung Chung, Fang-Ju Lin","doi":"10.2147/PTT.S606150","DOIUrl":"10.2147/PTT.S606150","url":null,"abstract":"<p><strong>Background: </strong>Generalized pustular psoriasis (GPP) is a rare and severe inflammatory disease characterized by widespread pustular eruptions and systemic inflammation.</p><p><strong>Objective: </strong>To evaluate the clinical characteristics and disease burden of patients with GPP in Taiwan using a national claims database.</p><p><strong>Methods: </strong>Patients with GPP and no prior diagnosis of psoriasis vulgaris (PV) who experienced an incident flare between January 1, 2017, and September 30, 2020, were identified from Taiwan's National Health Insurance Database. Clinical characteristics, comorbidities, and treatment patterns were described. Recurrent flare frequency, healthcare resource utilization (HCRU) and costs were compared with those of a propensity score-matched PV cohort at a ratio of up to 1:4. Outpatient-managed flares were classified as moderate, whereas hospitalized flares were classified as severe.</p><p><strong>Results: </strong>A total of 245 patients with GPP were included (mean age 51.3 years; 49.8% male). During follow-up, 1,156 moderate-to-severe flares were identified. Compared with matched patients with PV, patients with GPP had a higher recurrent flare rate (rate ratio 1.14; 95% CI 1.06-1.23). Patients with GPP also had greater HCRU, including more outpatient visits (incidence rate ratio [IRR] 1.03 [95% CI 1.01-1.05]), emergency room visits (IRR 1.33, 95% CI 1.19-1.49), and hospital admissions (IRR 1.69 [1.50-1.91]). Median monthly healthcare costs were approximately twice as high among patients with GPP as among matched patients with PV.</p><p><strong>Conclusion: </strong>Patients with GPP experienced recurrent flares, greater healthcare utilization, and higher healthcare costs than matched patients with PV, underscoring the substantial real-world clinical and economic burden of GPP.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"606150"},"PeriodicalIF":5.2,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional Inflammatory Mechanisms and Hematological/Coagulation Dysregulation in Psoriasis Complicated with Atherosclerosis: A Retrospective Hospital-Based Case-Control Study Leveraging the SH-YIMED Clinical Database.","authors":"Miao Zhang, Munsoon Hong, Ruiqing Cao, Jiale Chen, Liu Liu, Xiaoying Sun, Seokgyeong Hong, Xin Li","doi":"10.2147/PTT.S543978","DOIUrl":"10.2147/PTT.S543978","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic inflammatory skin disease associated with systemic inflammation, abnormal hemorheology, and coagulation dysfunction, all of which contribute to the development of atherosclerosis (AS). Inflammation and coagulation are closely intertwined processes; however, studies on the specific profiles of hemorheological and coagulation indices and their synergistic mechanisms remain limited.</p><p><strong>Objective: </strong>To compare differences in hemorheological and coagulation parameters and preliminarily elucidate the regulatory mechanism of the <i>inflammation-hemorheology-coagulation axis</i>.</p><p><strong>Methods: </strong>A total of 439 patients with psoriasis and 198 controls were enrolled; after PSM, 206 cases and 126 controls were included. All participants underwent vascular ultrasonography between May 2014 and February 2025. Patients were divided into the case group (psoriasis with AS) and control group (psoriasis without AS) based on vascular ultrasound and clinical assessment by specialized clinicians. PSM was used to balance baseline confounders, and sample sizes varied due to missing data. Statistical analyses included Spearman correlation and multivariate logistic regression.</p><p><strong>Results: </strong>The case group had higher fibrinogen (FIB) levels (3.54 vs. 3.11, <i>P</i> = 0.005, Cohen's d = 0.163) and shorter activated partial thromboplastin time (APTT) (26.40 vs. 27.60 s, <i>P</i> = 0.002, Cohen's d = 0.181). FIB showed the strongest association, with a correlation coefficient of 0.56 (<i>P</i> < 0.001) for systemic immune inflammation index (SII) and 0.39 (<i>P</i> < 0.001) for neutrophil-to-lymphocyte ratio (NLR) in the case group, and there was a strong positive correlation between SII and FIB (<i>r</i> = 0.56, <i>P</i> < 0.001). Psoriasis inflammation directly promoted vascular inflammation with a large effect size (β = 0.45, <i>P</i> < 0.001). Multivariate logistic regression analysis showed WBV (whole blood viscosity) (1 mPa·s) was the strongest predictor, with an OR of 1.752 (95% confidence interval [CI]: 1.314-2.651, <i>P</i> < 0.001).</p><p><strong>Limitations: </strong>Selection and recall biases of retrospective single-center studies.</p><p><strong>Conclusion: </strong>Patients with psoriasis, particularly those with severe disease, long disease duration, or complications from other thrombotic factors, should be closely monitored for hemorheological and coagulation parameters to prevent cardiovascular disease occurrence.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"543978"},"PeriodicalIF":5.2,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13310403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148347298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammaging and Senescence-Associated Secretory Phenotype (SASP) in Psoriasis - A Narrative Review of Potential Mechanisms and Anti-Inflammaging Strategies.","authors":"Kinga Filipek, Julia Nowowiejska-Purpurowicz, Iwona Flisiak","doi":"10.2147/PTT.S598115","DOIUrl":"10.2147/PTT.S598115","url":null,"abstract":"<p><p>Psoriasis is a common chronic dermatological disease, affecting approximately 1-3% of the global population, and is associated with numerous comorbidities, impaired quality of life, and reduced life expectancy compared with the general population. The pathogenesis of psoriasis is complex and multifactorial, involving genetic susceptibility, external environmental factors, and immune system dysregulation. Psoriasis is perceived as a systemic disorder associated with a systemic inflammatory condition. In psoriasis, a chronically activated immune response results in the expression of numerous pro-inflammatory mediators, which enhance and sustain the inflammatory feedback loop, thereby exacerbating cell senescence. Senescent cells adopt a hypersecretory state called senescence-associated secretory phenotype (SASP). Multiple SASP-related mediators are dysregulated in psoriasis, including pro-inflammatory cytokines, chemokines, growth factors, proteases and regulators, soluble or shed receptors and ligands, some of which may serve as biomarkers or therapeutic targets. Therefore, psoriasis is closely associated with immune dysregulation and inflammaging, which refers to a chronic, low-grade inflammatory state with exacerbated cellular senescence. The relationship between psoriasis, inflammation, and cellular senescence is multidirectional, and might be considered in two hypothetical scenarios of cause-and-effect relationship. A persistent pro-inflammatory state might promote cellular senescence and SASP upregulation, which in turn may trigger immunological alterations characteristic of psoriasis, or psoriasis and associated dysregulation of the immune system leading to systemic inflammation and thereby senescence. Hence, it is essential to clarify the mechanisms of inflammaging and the role of SASP in psoriasis. It may support the development of the therapeutic strategies that take into consideration comorbidities and their shared inflammatory background with psoriasis, enabling more precise assessment of the disease.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"598115"},"PeriodicalIF":5.2,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13225018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunosenescence in Older Patients with Psoriasis: Mechanistic Insights and Opportunities for Biologic Therapy.","authors":"Wenjie Wang, Shuying Zha, Liyun Sun, Dongmei Zhou","doi":"10.2147/PTT.S604199","DOIUrl":"10.2147/PTT.S604199","url":null,"abstract":"<p><p>Psoriasis is a chronic systemic inflammatory disease that is increasingly seen in older patients. As the immune system ages, the mechanisms that normally keep immune responses in balance become less precise. The adaptive immune system is reshaped both quantitatively and structurally, whereas innate immunity becomes less well regulated rather than simply less active. Age-related changes in the skin microenvironment may also help sustain local inflammatory signaling. In older patients with psoriasis, these age-related immune changes intersect with the pathways already known to drive disease. Th17 and cytotoxic CD8⁺ T (Tc17) responses remain prominent, control of antigen-presenting cells (APCs) is less tightly regulated, and natural killer (NK) cell function is also altered. These changes help sustain inflammation and further compromise the epidermal barrier. Treatment decisions are made more complex by common comorbidities, especially cardiovascular disease and metabolic syndrome. Biologic agents targeting TNF-α, IL-12/23, IL-23, IL-17, and IL-36 have markedly expanded the therapeutic options for psoriasis. Direct evidence in older patients with psoriasis remains limited, but the studies available so far suggest that treatment efficacy is broadly comparable to that seen in younger populations. Even so, immune aging may still affect both susceptibility to infection and the likelihood of remaining on treatment over time. TNF inhibitors remain particularly useful in patients with systemic inflammatory comorbidities, although infection risk requires close attention. IL-12/23 inhibitors offer the advantage of dual cytokine blockade. Selective IL-23 inhibitors allow more focused control of Th17-driven inflammation while leaving Th1 function relatively preserved. IL-17 inhibitors are often associated with rapid clinical improvement, whereas IL-36 inhibitors may be particularly promising in pustular disease. Clarifying how immunosenescence shapes disease behavior and treatment response in older patients should make it easier to individualize therapy.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"604199"},"PeriodicalIF":5.2,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148145687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Predictive Models for NB-UVB Treatment Efficacy and Safety in Psoriasis.","authors":"Yingyuan Yu, Bingjie Li, Yu Wang, Zhengkai Qu, Xin Wang, Yuxiong Jiang, Xiaoyuan Zhong, Youdong Chen, Dawei Huang, Xinling Bi, Jiajing Lu, Yangfeng Ding, Yu Gong, Jun Gu, Xilin Zhang, Yuling Shi","doi":"10.2147/PTT.S609637","DOIUrl":"10.2147/PTT.S609637","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic inflammatory skin disease. Narrow-band ultraviolet B (NB-UVB) phototherapy is an effective, cost-efficient, and safe treatment for plaque psoriasis; however, predictors of treatment response remain limited.</p><p><strong>Objective: </strong>To develop predictive models for the efficacy and safety of NB-UVB phototherapy in patients with plaque psoriasis.</p><p><strong>Methods: </strong>A total of 252 patients with plaque psoriasis were enrolled and received 12 weeks of NB-UVB phototherapy. Baseline clinical data and blood samples for genetic analysis were collected. A genome-wide association study (GWAS) was performed to identify single-nucleotide polymorphisms (SNPs) associated with treatment response and adverse events (AEs).</p><p><strong>Results: </strong>Using a suggestive genome-wide significance threshold (<i>P</i> < 1×10^-5), the <i>SLC7A13</i> rs35314286 TA allele and <i>DYNC1H1</i> rs941636 A allele showed suggestive associations with better efficacy after 4 weeks of NB-UVB treatment. Seven <i>ATP2B2</i> SNPs and ten <i>PSMB7</i> SNPs showed suggestive associations with achievement of Psoriasis area and severity index (PASI) 75 at week 12. Two <i>KCNA2</i> SNPs, seven <i>THSD7B</i> SNPs, and one <i>TENM4</i> SNP were identified as candidate markers for the occurrence of AEs.</p><p><strong>Conclusion: </strong>Predictive models of NB-UVB treatment response in psoriasis were subsequently established and achieved area under the curve (AUC) values ranging from 0.80 to 0.85. Further validation in independent external cohorts is needed before clinical application.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"609637"},"PeriodicalIF":5.2,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paraneoplastic Papuloerythroderma of Ofuji Masquerading as Worsening Psoriasis.","authors":"Megan Hauptman, Nikhil Mehta, Frank Wang, Lori Lowe, Mio Nakamura","doi":"10.2147/PTT.S608704","DOIUrl":"10.2147/PTT.S608704","url":null,"abstract":"<p><p>Paraneoplastic papuloerythroderma of Ofuji (PEO) is a rare cause of exfoliative erythroderma characterized by intensely pruritic, generalized erythema and scale with relative sparing of the skin folds (deck-chair sign) and is frequently associated with underlying malignancy, most commonly cutaneous T-cell lymphoma (CTCL). We present a unique case of paraneoplastic PEO in a patient with a history of plaque psoriasis whose rash suddenly began to worsen despite treatments for psoriasis. He developed diffuse brightly erythematous plaques with sparing fo the skin folds and hyperkeratotic, fissured plaques on the palms and soles. This ultimately led to hospitalization for erythroderma. Upon further work up, he was found to have squamous cell carcinoma of the lung by computed tomography. This case underscores that abrupt erythrodermic worsening in a patient with known psoriasis should prompt evaluation for an underlying paraneoplastic process rather than being attributed to psoriasis progression alone.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"608704"},"PeriodicalIF":5.2,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13207852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148044997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.","authors":"Ulrich Mrowietz, Rachel Sommer, Ziad Reguiai, Sascha Gerdes, Esteban Daudén, Wolfgang Weger, Julia-Tatjana Maul, Luigi Naldi, Pierre-Dominique Ghislain, Philip M Laws, Elke M G J De Jong, Sicily Mburu, Volker Koscielny, Eric Massana, Victor Sapena, Arnau Domenech, Ismail Kasujee, Matthias Augustin","doi":"10.2147/PTT.S590189","DOIUrl":"10.2147/PTT.S590189","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis extends beyond skin manifestations and significantly impacts patients' psychological health, social interactions, and daily functioning. The main objective was to assess the 2-year effect of tildrakizumab, an interleukin-23p19 inhibitor, on the skin, the psychological well-being and the health-related quality of life (HRQoL) of people with psoriatic disease in real-world.</p><p><strong>Patients and methods: </strong>The POSITIVE study is a 24-month, prospective observational multinational study enrolling adults with moderate-to-severe plaque psoriasis treated with tildrakizumab according to clinical practice. Outcome measurements included the 5-item WHO Well-being Index (WHO-5), Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index-Relevant (DLQI-R).</p><p><strong>Results: </strong>785 patients were included. The mean (95% CI) WHO-5 score increased from 53.7 (52.2, 55.3) at baseline to 63.2 (61.5, 64.8) at W16 and continued improving over time: 65.9 (64.0, 67.9) at W52 and 70.4 (68.1, 72.7) at W104. The mean (95% CI) PASI decreased from 12.9 (12.3, 13.5) at baseline to 2.4 (2.2, 2.7) at W16 and was maintained until W104 [1.3 (1.1, 1.5)]. At W104, 87.9/79.0/65.1% of patients maintained PASI ≤3/≤2/≤1. Drug survival due to lack of effectiveness or adverse events (AE) was 87.8% and 96.3% after 2 years. The mean (95% CI) DLQI-R score decreased from 12.0 (11.4, 12.6) at baseline to 3.1 (2.6, 3.6) W52 and 2.1 (1.7, 2.5) at W104. At the final analysis, 11.1% of patients had ≥1 related AE.</p><p><strong>Conclusion: </strong>Treatment with tildrakizumab delivered sustained and holistic long-term health for moderate to severe psoriasis over 2 years by consistently improving patients' psychological well-being, life and clinical outcomes with a favourable safety profile.</p><p><strong>Clinicaltrialsgov id: </strong>NCT04823247.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"16 ","pages":"590189"},"PeriodicalIF":5.2,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}